Related Experiment Video
Updated: Mar 3, 2026

Advanced Glycation End-Products Sensitize Human Sensory-Like Neuron Cells to Capsaicin-Induced Calcium Influx
Published on: May 2, 2025
Expression of the receptor for advanced glycation end products in acquired reactive perforating collagenosis
Gulsen Akoglu1, Nuran Sungu2, Eda Karaismailoglu3
1Department of Dermatovenereology, Ataturk Training and Research Hospital, Ankara, Turkey.
Background:
Acquired reactive perforating collagenosis (ARPC) is a rare skin disorder characterized by transepidermal elimination of dermal collagen. There is little data regarding the pathogenesis of ARPC. The receptor for advanced glycation end products (RAGE) is a multiligand transmembrane receptor that plays an important role in inflammatory responses and may be involved in the pathogenesis of ARPC.
Aim:
To explore the expression of RAGE in ARPC.
Methods:
Paraffin-embedded punch biopsy specimens of 41 patients with ARPC and of 11 healthy controls with normal skin were obtained from the Department Of Pathology. Clinical data of all patients were reviewed from the medical files. All specimens were stained immunohistochemically with antibody to RAGE (Anti-RAGE). The intensity of RAGE expression was assessed semi-quantitatively on epidermal cells, microvascular endothelium, dermal fibroblasts and inflammatory cells and graded as 0 (no staining), 1 (weak), 2 (moderate) and 3 (strong). The patients were divided into diabetic and nondiabetic groups for analysis.
Results:
RAGE expression in microvascular endothelium, inflammatory cells and fibroblasts of patients with ARPC was more intense than normal tissues of healthy participants (P values are 0.005, 0.017 and P > 0.05).
Limitations:
Our method of assessment of RAGE expression was semi-quantitative.
Conclusion:
We observed an overexpression of RAGE in lesional samples of patients with ARPC which was independent of the presence of diabetes.
Insights
Acquired reactive perforating collagenosis (ARPC) shows increased expression of the receptor for advanced glycation end products (RAGE). This RAGE overexpression in ARPC skin lesions is independent of diabetes status.
Area of Science:
- Dermatology
- Pathology
- Immunohistochemistry
Background:
- Acquired reactive perforating collagenosis (ARPC) is a rare skin condition involving collagen elimination.
- The pathogenesis of ARPC is not well understood.
- The receptor for advanced glycation end products (RAGE) is implicated in inflammatory processes.
Purpose of the Study:
- To investigate the expression levels of RAGE in patients with ARPC.
- To determine if RAGE expression differs between ARPC patients and healthy controls.
Main Methods:
- Immunohistochemical staining for RAGE was performed on skin biopsy specimens from 41 ARPC patients and 11 healthy controls.
- RAGE expression intensity was semi-quantitatively assessed in epidermal cells, microvascular endothelium, dermal fibroblasts, and inflammatory cells.
- Patients were analyzed based on diabetic and non-diabetic status.
Main Results:
- RAGE expression was significantly more intense in the microvascular endothelium and inflammatory cells of ARPC patients compared to controls (p=0.005 and p=0.017, respectively).
- Increased RAGE expression was also observed in dermal fibroblasts, though not statistically significant (p > 0.05).
Conclusions:
- The study observed an overexpression of RAGE in lesional samples from ARPC patients.
- This RAGE overexpression in ARPC is independent of the presence of diabetes.
More Related Videos
04:42Author Spotlight: Analyzing Fibrosis Development in Chronic Lung Allograft Rejection Using Picrosirius Red Staining in Mouse Models
Published on: March 21, 2025
04:50Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research
Published on: August 4, 2023
Related Concept Videos
Proteoglycans
Rheumatic Heart Disease I: Introduction
Type IV Collagen of Basal Lamina
A type IV collagen molecule has six alpha chains which can...
Matrix Proteoglycans and Glycoproteins
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...